Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls.
Full description
This study will evaluate the following objectives:
Primary Objectives:
Secondary Objectives:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Inclusion: treatment of favorable risk features:
Ann Arbor IA or IIA with:
Non-bulky mediastinal disease (<33% mediastinal to thoracic ratio on chest x ray)
Ann Arbor stage IA or IIA with any of the following features: (1) "E" lesions (s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)
Inclusion: unfavorable risk features:
Stage must be classified as one of the following:
Primary purpose
Allocation
Interventional model
Masking
296 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal